During Q3 2018 the big money sentiment increased to 1.39. That’s change of 0.15, from 2018Q2’s 1.24. 18 investors sold all, 76 reduced holdings as Seattle Genetics, Inc. ratio is positive. 73 increased holdings while 58 funds took holdings. Funds hold 158.11 million shares thus 1.19% less from 2018Q2’s 160.01 million shares.
State Common Retirement Fund accumulated 253,700 shs. Dupont holds 0.01% or 6,500 shs. 77,317 are held by Barclays Public Ltd Liability. California Public Employees Retirement System, California-based fund reported 172,092 shs. Northwestern Mutual Wealth Mngmt Company has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). 200 are owned by Mark Sheptoff Fincl Planning Lc. 203,859 are owned by D E Shaw &. Ca owns 22,626 shs or 0.54% of their US capital. Commerzbank Aktiengesellschaft Fi invested in 0.04% or 50,000 shs. Eagle Asset Inc reported 568,902 shs stake. Verity Asset Mgmt Inc invested in 0.4% or 5,218 shs. Ls Inv Advsrs Ltd Liability Com has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Moreover, Etrade Capital Mngmt Limited Company has 0.02% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 10,405 shs. Minnesota-based Us National Bank De has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). First City Inc holds 0.27% or 5,350 shs in its capital.

Seattle Genetics, Inc. registered $16.44 million net activity with 0 insider purchases and 18 insider sales since August 21, 2018. Shares for $410,502 were sold by HIMES VAUGHN B on Monday, August 27. Cline Darren S sold $355,125 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, August 27. On Tuesday, January 8 GRYSKA DAVID W also sold $325,200 worth of Seattle Genetics, Inc. (NASDAQ:SGEN). On Monday, August 27 a trade for 5,427 shs valued at $402,856 was made by SIMPSON TODD E. On Monday, August 27 a trade for 4,123 shs valued at $306,058 was made by LIU JEAN I.

Seattle Genetics Inc (NASDAQ:SGEN) had an increase of its short interest by 6.46%. FINRA published in February SGEN’s total 12.54M short interest. The up change of 6.46% from 11.78 million shares was reported. 11 days will cost SGEN with 1.11M average volume to recover its former position. 11.82% is Seattle Genetics Inc float short.

Ticker’s shares touched $71.48 during the last trading session after 4.24% change.Currently Seattle Genetics, Inc. is uptrending after 5.90% change in last February 16, 2018. SGEN has 848,926 shares volume. SGEN outperformed by 5.90% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The company has $11.48 billion market cap. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Currently it has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

A total of 3 analysts rate Seattle Genetics (NASDAQ:SGEN) as follows: 2 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 67% are bullish. (NASDAQ:SGEN) has 4 ratings reports on Feb 16, 2019 according to StockzIntelligence. The stock rating was maintained by Barclays Capital with “Overweight” on Wednesday, October 3. On Tuesday, November 27 the firm has “Hold” rating by Piper Jaffray given. The stock rating was maintained by Barclays Capital with “Overweight” on Friday, October 26.

For more Seattle Genetics, Inc. (NASDAQ:SGEN) news published briefly go to: Investorplace.com, Seekingalpha.com, Marketwatch.com, Fool.com or Nasdaq.com. The titles are as follows: “5 Biotech Stocks That Could Face M&A Next! – Investorplace.com” published on January 10, 2019, “Seattle Genetics’ Adcetris successful in late-stage study in first-line PTCL – Seeking Alpha” on October 01, 2018, “Seattle Genetics stock jumps 6% after new FDA approval for lymphoma treatment – MarketWatch” with a publish date: November 16, 2018, “Why Seattle Genetics Jumped Higher Today – The Motley Fool” and the last “Bullish Two Hundred Day Moving Average Cross – SGEN – Nasdaq” with publication date: January 08, 2019.